Ra Capital Management, L.P. Avidity Biosciences, Inc. Transaction History
Ra Capital Management, L.P.
- $7.17 Billion
- Q3 2024
A detailed history of Ra Capital Management, L.P. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Ra Capital Management, L.P. holds 6,300,408 shares of RNA stock, worth $275 Million. This represents 4.04% of its overall portfolio holdings.
Number of Shares
6,300,408
Previous 5,400,408
16.67%
Holding current value
$275 Million
Previous $221 Million
31.17%
% of portfolio
4.04%
Previous 3.32%
Shares
8 transactions
Others Institutions Holding RNA
# of Institutions
256Shares Held
107MCall Options Held
224KPut Options Held
161K-
Price T Rowe Associates Inc Baltimore, MD10.6MShares$464 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.23MShares$403 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$376 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.13MShares$355 Million5.95% of portfolio
-
Wellington Management Group LLP Boston, MA7.03MShares$307 Million0.06% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $2.28B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...